Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.

Rolfo C, de Vos-Geelen J, Isambert N, Molife LR, Schellens JHM, De Grève J, Dirix L, Grundtvig-Sørensen P, Jerusalem G, Leunen K, Mau-Sørensen M, Plummer R, Learoyd M, Bannister W, Fielding A, Ravaud A.

Clin Pharmacokinet. 2019 Sep;58(9):1165-1174. doi: 10.1007/s40262-019-00754-4.

PMID:
30877569
2.

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.

Evans TRJ, Dean E, Molife LR, Lopez J, Ranson M, El-Khouly F, Zubairi I, Savulsky C, Reyderman L, Jia Y, Sweeting L, Greystoke A, Barriuso J, Kristeleit R.

Br J Cancer. 2019 Feb;120(4):379-386. doi: 10.1038/s41416-019-0377-x. Epub 2019 Jan 25.

3.

Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.

Plummer R, Verheul HM, De Vos FYFL, Leunen K, Molife LR, Rolfo C, Grundtvig-Sørensen P, De Grève J, Rottey S, Jerusalem G, Italiano A, Spicer J, Dirix L, Goessl C, Birkett J, Spencer S, Learoyd M, Bailey C, Dean E.

Adv Ther. 2018 Nov;35(11):1945-1964. doi: 10.1007/s12325-018-0804-z. Epub 2018 Oct 15.

PMID:
30324586
4.

Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.

Coleman N, Michalarea V, Alken S, Rihawi K, Lopez RP, Tunariu N, Petruckevitch A, Molife LR, Banerji U, De Bono JS, Welsh L, Saran F, Lopez J.

J Neurooncol. 2018 Aug;139(1):107-116. doi: 10.1007/s11060-018-2847-z. Epub 2018 Apr 10.

PMID:
29637509
5.

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.

Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA.

Oncotarget. 2017 Nov 6;8(61):104430-104443. doi: 10.18632/oncotarget.22303. eCollection 2017 Nov 28.

6.

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.

Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.

Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.

7.

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB, Yap TA.

Eur J Cancer. 2017 May;76:52-59. doi: 10.1016/j.ejca.2017.01.020. Epub 2017 Mar 6.

PMID:
28273485
8.

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.

Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, Roxburgh P, Giordano H, Jaw-Tsai S, Goble S, Plummer R.

Br J Cancer. 2017 Mar 28;116(7):884-892. doi: 10.1038/bjc.2017.36. Epub 2017 Feb 21.

9.

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.

Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O'Brien MER, Yap TA.

Eur J Cancer. 2017 Apr;75:56-62. doi: 10.1016/j.ejca.2016.12.026. Epub 2017 Feb 17.

PMID:
28214659
10.

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.

Dirix L, Swaisland H, Verheul HM, Rottey S, Leunen K, Jerusalem G, Rolfo C, Nielsen D, Molife LR, Kristeleit R, Vos-Geelen J, Mau-Sørensen M, Soetekouw P, van Herpen C, Fielding A, So K, Bannister W, Plummer R.

Clin Ther. 2016 Oct;38(10):2286-2299. doi: 10.1016/j.clinthera.2016.08.010. Epub 2016 Oct 10.

PMID:
27745744
11.

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.

Mateo J, Moreno V, Gupta A, Kaye SB, Dean E, Middleton MR, Friedlander M, Gourley C, Plummer R, Rustin G, Sessa C, Leunen K, Ledermann J, Swaisland H, Fielding A, Bannister W, Nicum S, Molife LR.

Target Oncol. 2016 Jun;11(3):401-15. doi: 10.1007/s11523-016-0435-8.

12.

Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.

Khan KH, Wong M, Rihawi K, Bodla S, Morganstein D, Banerji U, Molife LR.

Oncologist. 2016 Jul;21(7):855-60. doi: 10.1634/theoncologist.2015-0248. Epub 2016 May 5.

13.

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.

Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL.

Ann Oncol. 2016 Jun;27(6):1013-9. doi: 10.1093/annonc/mdw133. Epub 2016 Mar 8.

14.

Phase I trial outcomes in older patients with advanced solid tumours.

Khan KH, Yap TA, Ring A, Molife LR, Bodla S, Thomas K, Zivi A, Smith A, Judson I, Banerji U, de Bono JS, Kaye SB.

Br J Cancer. 2016 Feb 2;114(3):262-8. doi: 10.1038/bjc.2015.477. Epub 2016 Jan 12.

15.

Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.

Geuna E, Roda D, Rafii S, Jimenez B, Capelan M, Rihawi K, Montemurro F, Yap TA, Kaye SB, De Bono JS, Molife LR, Banerji U.

Br J Cancer. 2015 Dec 1;113(11):1541-7. doi: 10.1038/bjc.2015.373. Epub 2015 Nov 10.

16.

Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.

Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Grève J, Lolkema MP, Soetekouw P, Mau-Sørensen M, Nielsen D, Spicer J, Fielding A, So K, Bannister W, Molife LR.

Cancer Chemother Pharmacol. 2015 Oct;76(4):723-9. doi: 10.1007/s00280-015-2836-2. Epub 2015 Aug 5.

PMID:
26242220
17.

Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.

Rafii S, Roda D, Geuna E, Jimenez B, Rihawi K, Capelan M, Yap TA, Molife LR, Kaye SB, de Bono JS, Banerji U.

Clin Cancer Res. 2015 Apr 15;21(8):1869-76. doi: 10.1158/1078-0432.CCR-14-2424. Epub 2015 Feb 3.

18.

A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.

Molife LR, Dean EJ, Blanco-Codesido M, Krebs MG, Brunetto AT, Greystoke AP, Daniele G, Lee L, Kuznetsov G, Myint KT, Wood K, de Las Heras B, Ranson MR.

Clin Cancer Res. 2014 Dec 15;20(24):6284-94. doi: 10.1158/1078-0432.CCR-14-0409. Epub 2014 Oct 2.

19.

Cancer therapeutics: Targeting the apoptotic pathway.

Khan KH, Blanco-Codesido M, Molife LR.

Crit Rev Oncol Hematol. 2014 Jun;90(3):200-19. doi: 10.1016/j.critrevonc.2013.12.012. Epub 2013 Dec 18. Review.

PMID:
24507955
20.

Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.

Molife LR, Omlin A, Jones RJ, Karavasilis V, Bloomfield D, Lumsden G, Fong PC, Olmos D, O'Sullivan JM, Pedley I, Hickish T, Jenkins P, Thompson E, Oommen N, Wheatley D, Heath C, Temple G, Pelling K, de Bono JS.

Future Oncol. 2014 Feb;10(2):219-31. doi: 10.2217/fon.13.250.

PMID:
24490608
21.

Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit.

Khan K, Ang JE, Starling N, Sclafani F, Shah K, Judson I, Molife LR, Banerji U, de Bono JS, Cunningham D, Kaye SB.

Gastric Cancer. 2014 Oct;17(4):621-629. doi: 10.1007/s10120-013-0328-9. Epub 2014 Jan 21.

22.

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.

Molife LR, Yan L, Vitfell-Rasmussen J, Zernhelt AM, Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E, Siu LL, Patnaik A, Papadopoulos KP, de Bono JS, Tolcher AW, Minton S.

J Hematol Oncol. 2014 Jan 3;7:1. doi: 10.1186/1756-8722-7-1.

23.

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.

Molife LR, Rudman SM, Alam S, Tan DS, Kristeleit H, Middleton G, Propper D, Bent L, Stopfer P, Uttenreuther-Fischer M, Wallenstein G, de Bono J, Spicer J.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1213-22. doi: 10.1007/s00280-013-2286-7. Epub 2013 Oct 2.

PMID:
24085260
24.

First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.

Brunetto AT, Ang JE, Lal R, Olmos D, Molife LR, Kristeleit R, Parker A, Casamayor I, Olaleye M, Mais A, Hauns B, Strobel V, Hentsch B, de Bono JS.

Clin Cancer Res. 2013 Oct 1;19(19):5494-504. doi: 10.1158/1078-0432.CCR-13-0735. Epub 2013 Sep 24.

25.

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.

Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, Yap TA, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J.

Ann Oncol. 2013 May;24(5):1416-8. doi: 10.1093/annonc/mdt074. Epub 2013 Mar 22. No abstract available.

26.

Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.

Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Reis Filho JS, Moreno V, Mateo J, Molife LR, De Bono J, Kaye S, Lord CJ, Ashworth A.

J Pathol. 2013 Feb;229(3):422-9. doi: 10.1002/path.4140.

PMID:
23165508
27.

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers.

Perkins G, Yap TA, Pope L, Cassidy AM, Dukes JP, Riisnaes R, Massard C, Cassier PA, Miranda S, Clark J, Denholm KA, Thway K, Gonzalez De Castro D, Attard G, Molife LR, Kaye SB, Banerji U, de Bono JS.

PLoS One. 2012;7(11):e47020. doi: 10.1371/journal.pone.0047020. Epub 2012 Nov 7.

28.

Association of creatine kinase and skin toxicity in phase I trials of anticancer agents.

Moreno Garcia V, Thavasu P, Blanco Codesido M, Molife LR, Vitfell Pedersen J, Puglisi M, Basu B, Shah K, Iqbal J, de Bono JS, Kaye SB, Banerji U.

Br J Cancer. 2012 Nov 20;107(11):1797-800. doi: 10.1038/bjc.2012.482. Epub 2012 Oct 25.

29.

Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials.

Basu B, Vitfell-Pedersen J, Moreno Garcia V, Puglisi M, Tjokrowidjaja A, Shah K, Malvankar S, Anghan B, de Bono JS, Kaye SB, Molife LR, Banerji U.

Oncology. 2012;83(4):177-82. doi: 10.1159/000341152. Epub 2012 Aug 7.

30.

Combining antiangiogenics to overcome resistance: rationale and clinical experience.

Moreno Garcia V, Basu B, Molife LR, Kaye SB.

Clin Cancer Res. 2012 Jul 15;18(14):3750-61. doi: 10.1158/1078-0432.CCR-11-1275. Epub 2012 Apr 30. Review.

31.

Targeting the DNA damage response in oncology: past, present and future perspectives.

Basu B, Yap TA, Molife LR, de Bono JS.

Curr Opin Oncol. 2012 May;24(3):316-24. doi: 10.1097/CCO.0b013e32835280c6. Review.

PMID:
22476188
32.

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience.

Molife LR, Alam S, Olmos D, Puglisi M, Shah K, Fehrmann R, Trani L, Tjokrowidjaja A, de Bono JS, Banerji U, Kaye SB.

Ann Oncol. 2012 Aug;23(8):1968-73. doi: 10.1093/annonc/mds030. Epub 2012 Mar 9.

33.

FGF receptor inhibitors: role in cancer therapy.

Daniele G, Corral J, Molife LR, de Bono JS.

Curr Oncol Rep. 2012 Apr;14(2):111-9. doi: 10.1007/s11912-012-0225-0. Review.

PMID:
22311684
34.

Toward a better dialogue between neuro-oncologists and phase I investigators.

Massard C, Sandhu S, Blanco M, Papadatos-Pastos D, Carden C, De Bono J, Saran F, Molife LR, Kaye SB, Soria JC, Banerji U.

J Clin Oncol. 2012 Feb 10;30(5):562-3; author reply 563-4. doi: 10.1200/JCO.2011.39.8347. Epub 2012 Jan 3. No abstract available.

PMID:
22215743
35.

Belinostat: clinical applications in solid tumors and lymphoma.

Molife LR, de Bono JS.

Expert Opin Investig Drugs. 2011 Dec;20(12):1723-32. doi: 10.1517/13543784.2011.629604. Epub 2011 Nov 3. Review.

PMID:
22046971
36.

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.

Arkenau HT, Plummer R, Molife LR, Olmos D, Yap TA, Squires M, Lewis S, Lock V, Yule M, Lyons J, Calvert H, Judson I.

Ann Oncol. 2012 May;23(5):1307-13. doi: 10.1093/annonc/mdr451. Epub 2011 Oct 19.

37.

Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials.

Blanco Codesido M, Tesainer Brunetto A, Frentzas S, Moreno Garcia V, Papadatos-Pastos D, Pedersen JV, Trani L, Puglisi M, Molife LR, Banerji U.

Oncology. 2011;81(2):135-40. doi: 10.1159/000330206. Epub 2011 Oct 6.

PMID:
21985828
38.

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

de Bono JS, Molife LR, Sonpavde G, Maroto JP, Calvo E, Cartwright TH, Loesch DM, Feit K, Das A, Zang EA, Wanders J, Agoulnik S, Petrylak DP.

Ann Oncol. 2012 May;23(5):1241-9. doi: 10.1093/annonc/mdr380. Epub 2011 Sep 7.

39.

Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies.

Yap TA, Olmos D, Molife LR, de Bono JS.

Expert Opin Investig Drugs. 2011 Sep;20(9):1293-304. doi: 10.1517/13543784.2011.602630. Epub 2011 Jul 22. Review.

PMID:
21777167
40.

Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.

Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, Ashworth A, Poole CJ, Weigelt B, Kaye SB, Molife LR.

Nat Rev Clin Oncol. 2011 May;8(5):302-6. doi: 10.1038/nrclinonc.2011.42. Epub 2011 Apr 5.

PMID:
21468130
41.

Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?

Postel-Vinay S, Gomez-Roca C, Molife LR, Anghan B, Levy A, Judson I, De Bono J, Soria JC, Kaye S, Paoletti X.

J Clin Oncol. 2011 May 1;29(13):1728-35. doi: 10.1200/JCO.2010.31.9236. Epub 2011 Mar 28.

PMID:
21444876
42.

A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition.

Brunetto AT, Ang JE, Olmos D, Tan D, Barriuso J, Arkenau HT, Yap TA, Molife LR, Banerji U, de Bono J, Judson I, Kaye S.

Eur J Cancer. 2010 Oct;46(15):2739-45. doi: 10.1016/j.ejca.2010.06.123. Epub 2010 Aug 11.

PMID:
20667711
43.

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.

Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, Yap TA, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, Leitzel K, Gualberto A, de Bono JS.

Br J Cancer. 2010 Jul 27;103(3):332-9. doi: 10.1038/sj.bjc.6605767. Epub 2010 Jul 13.

44.

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours.

Lassen U, Molife LR, Sorensen M, Engelholm SA, Vidal L, Sinha R, Penson RT, Buhl-Jensen P, Crowley E, Tjornelund J, Knoblauch P, de Bono JS.

Br J Cancer. 2010 Jun 29;103(1):12-7. doi: 10.1038/sj.bjc.6605726. Epub 2010 Jun 15.

45.

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS.

J Clin Oncol. 2010 Mar 20;28(9):1489-95. doi: 10.1200/JCO.2009.24.6819. Epub 2010 Feb 16.

46.

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.

Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr M, de Bono JS, Haluska P.

Lancet Oncol. 2010 Feb;11(2):129-35. doi: 10.1016/S1470-2045(09)70354-7. Epub 2009 Dec 23.

47.

Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor.

Carden CP, Molife LR, de Bono JS.

Mol Cancer Ther. 2009 Aug;8(8):2077-8. doi: 10.1158/1535-7163.MCT-09-0641. Epub 2009 Aug 11. No abstract available.

48.

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

Molife LR, Attard G, Fong PC, Karavasilis V, Reid AH, Patterson S, Riggs CE Jr, Higano C, Stadler WM, McCulloch W, Dearnaley D, Parker C, de Bono JS.

Ann Oncol. 2010 Jan;21(1):109-13. doi: 10.1093/annonc/mdp270. Epub 2009 Jul 16.

49.

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS.

J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26.

50.

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours.

Scott EN, Thomas AL, Molife LR, Ahmed S, Blagden S, Fong PC, Kowal K, McCoy C, Wiesinger H, Steward W, De Bono J.

Cancer Chemother Pharmacol. 2009 Jul;64(2):425-9. doi: 10.1007/s00280-009-0968-y. Epub 2009 Mar 12.

PMID:
19280191

Supplemental Content

Loading ...
Support Center